Clinical and pathological characteristics of 595 patients with PCs and correlation with TP53, PIK3CA, PTEN and AKT1 status
| Patient or cyst characteristics | Total | TP53, PIK3CA, PTEN and/or AKT1 | p Value | |
| Wild type | Mutant | |||
| Gender | n=595 | |||
| Woman | 341 | 328 (96%) | 13 (4%) | 0.014 |
| Man | 254 | 232 (92%) | 22 (9%) | |
| Mean age (range) (years) | 65.0 (15–93) | 64.8 (15–93) | 68.3 (45–84) | 0.107 |
| Symptomatic presentation | 198 | 183 (92%) | 15 (8%) | 0.267 |
| Location | n=626 | |||
| Head, neck and uncinate | 320 | 299 (93%) | 21 (7%) | 0.301 |
| Body and tail | 306 | 292 (95%) | 14 (5%) | |
| Mean cyst size (range) (cm) | 2.7 (0.8–21.0) | 2.7 (0.8–21.0) | 2.8 (0.9–5.2) | 0.739 |
| Cyst size ≥3 cm | 194 | 177 (91%) | 17 (9%) | 0.025 |
| Satisfactory cytological adequacy | 251 | 233 (93%) | 18 (7%) | 0.213 |
| Main duct dilatation | 104 | 92 (88%) | 12 (12%) | 0.008 |
| Presence of a mural nodule | 35 | 27 (77%) | 8 (23%) | <0.001 |
| Malignant cytopathology* | 10 | 3 (30%) | 7 (70%) | <0.001 |
| Mutations in KRAS and/or GNAS | 308 | 276 (90%) | 32 (10%) | <0.001 |
| Diagnostic pathology | n=102 | n=83 | n=19 | |
| Adenocarcinoma arising in an IPMN | 13 | 0 (0%) | 13 (100%) | |
| IPMN with high-grade dysplasia | 4 | 2 (50%) | 2 (50%) | <0.001† |
| MCN with high-grade dysplasia | 2 | 2 (100%) | 0 (0%) | |
| IPMN with low-grade dysplasia | 39 | 36 (92%) | 3 (8%) | |
| MCN with low-grade dysplasia | 8 | 7 (87%) | 1 (13%) | |
| Serous cystadenoma | 3 | 3 (100%) | 0 (0%) | |
| Cystic PanNET | 9 | 9 (100%) | 0 (0%) | |
| Non-neoplastic cysts | 24 | 24 (100%) | 0 (0%) | |
*Malignant cytopathology is defined as at least suspicious for adenocarcinoma.
†p Value corresponds to mucinous PCs with advanced neoplasia versus other PCs.
CEA, carcinoembryonic antigen; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; PanNET, pancreatic neuroendocrine tumour; PC, pancreatic cyst.